Does Vectura's US deal on respiratory drug mean FDA is softening on approval pathway?
This article was originally published in Scrip
Vectura has found a replacement US partner for its combination asthma/COPD product, VR315, marking a shift in what has been a major impasse for firms hoping to introduce generic versions of asthma combination products in the US.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.